Drug Profile
ARRY 382
Alternative Names: ARRY-382Latest Information Update: 20 Jun 2022
Price :
$50
*
At a glance
- Originator Array BioPharma
- Class Antineoplastics; Small molecules
- Mechanism of Action Macrophage colony stimulating factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer; Solid tumours
Most Recent Events
- 20 Jun 2022 Array Biopharma terminates a phase II trial in Solid tumours (Combination therapy, Late-stage disease) in USA (PO) due to insufficient efficacy (NCT02880371)
- 08 Oct 2021 Discontinued - Phase-I for Cancer (Metastatic disease) in USA (PO) (Pfizer pipeline, October 2021
- 08 Oct 2021 Discontinued - Phase-II for Solid tumours (Combination therapy, Late-stage disease) in USA (PO) (Pfizer pipeline, October 2021)